- Stocks
- Pharma & Healthcare
- Astal Lab
Astal Lab share price
NSE: ASTALLTDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Astal Lab at a glance
With a market capitalisation of ₹358 Cr, it ranks 1969th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 24.8% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹134 Cr (+471.2% year on year) and net profit ₹8 Cr (+180.3%), on a consolidated basis. Promoters held 4.53% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹358 CrRank 1969 on NSE
- Price to book
- 2.08×FY25
- ROE
- 24.8%FY25
- ROCE
- 34.7%FY25
- Debt to equity
- 0.37FY25
- Net profit margin
- 13.9%FY25
- Book value / share
- ₹36.56FY25
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Astal Lab quarterly results
| Quarter | Q4 FY25 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|
| Revenue | ₹23 Cr | ₹52 Cr | ₹134 Cr |
| Revenue YoY | — | — | +471.2% |
| Net profit | ₹3 Cr | ₹2 Cr | ₹8 Cr |
| Net profit YoY | — | — | +180.3% |
| Net margin | 11.7% | 4.5% | 5.7% |
| EPS | ₹2.80 | ₹2.19 | ₹2.04 |
Astal Lab financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr | ₹24 Cr | ₹64 Cr |
| Operating profit | −₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹12 Cr |
| Net profit | −₹0 Cr | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹9 Cr |
| EPS (₹) | −₹0.07 | ₹0.02 | −₹0.04 | ₹0.04 | ₹1.55 | ₹9.08 |
| Cash from operations | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | −₹6 Cr | −₹13 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹23 Cr | ₹36 Cr |
Astal Lab shareholding pattern
| Holder | 31 Dec 2025 | 14 Jan 2026 | 31 Mar 2026 | 20 May 2026 | 29 May 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 18.19% | 4.64% | 4.70% | 4.55% | 4.53% | 4.53% |
| Non-institutions | 81.81% | 95.36% | 95.30% | 95.45% | 95.47% | 95.47% |
Astal Lab vs peers
The listed Pharma & Healthcare companies nearest to Astal Lab by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| JENBURPHJenburkt Pharma | ₹902.75 | −0.27% | — | ₹398 Cr | 11.5 | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
| APPLAptus Pharma | — | — | — | ₹377 Cr | — | — |
| MEDICAMEQMedicamen Biotech | ₹267.20 | −2.25% | −12.9% | ₹362 Cr | 37 | — |
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
| AAREYDRUGSAarey Drugs & Pharmaceuticals | ₹111.83 | −2.31% | +33.9% | ₹317 Cr | 80.5 | — |
| LYKALABSLyka Labs | ₹86.04 | −1.99% | −9.0% | ₹311 Cr | — | — |
Ask anything about Astal Lab
Pivot answers on the live chart with evidence you can check, and tests strategies against ASTALLTD's own history. Try: “Why has ASTALLTD moved over the last three months?” · “Backtest a 50-day moving-average crossover on ASTALLTD over five years” · “Compare ASTALLTD with JENBURPH on margins and valuation”
Frequently asked questions about Astal Lab
What is the market cap of Astal Lab?
Astal Lab's market capitalisation is ₹358 Cr (₹358 Cr) at the 21 Oct 2026 close, ranking 1969th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Astal Lab?
Return on equity was 24.8% in FY25 and return on capital employed was 34.7% in FY25 (standalone figures).
Is Astal Lab a debt-free company?
No. Astal Lab's debt-to-equity ratio was 0.37 in FY25, with total debt of ₹0 Cr.
What were Astal Lab's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Astal Lab reported revenue of ₹134 Cr, +471.2% year on year, and net profit of ₹8 Cr, +180.3% year on year.
What is the shareholding pattern of Astal Lab?
As of 30 Jun 2026: promoters 4.53%, non-institutions 95.47%.
Who are Astal Lab's competitors?
The listed Pharma & Healthcare companies closest to Astal Lab by market cap are Jenburkt Pharma, Transchem, Aptus Pharma, Medicamen Biotech, Aarey Drugs & Pharmaceuticals and Lyka Labs.
Is Astal Lab a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Astal Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTALLTD against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text